• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by ZimVie Inc. (Amendment)

    2/14/24 11:40:55 AM ET
    $ZIMV
    Medical/Dental Instruments
    Health Care
    Get the next $ZIMV alert in real time by email
    SC 13G/A 1 zimv_13g.htm

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G/A

    Under the Securities Exchange Act of 1934

     

    (Amendment No. 1)*

     

     

    ZimVie, Inc.
    (Name of Issuer)
     
    Common Stock, $0.01 par value
    (Title of Class of Securities)
     
    98888T107
    (CUSIP Number)
     
    December 31, 2023
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x Rule 13d-1(b)
    o Rule 13d-1(c)
    o Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 98888T10713G/APage 1 of 9 Pages

     

     

     

     

    1.

     

    NAME OF REPORTING PERSONS

    Kent Lake Partners LP

     

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (see instructions)

    (a)     o

    (b)     o

     

     

    3.

     

    SEC USE ONLY

     

     

    4.

     

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH

     

    5.

     

    SOLE VOTING POWER

    0

     

     

    6.

     

    SHARED VOTING POWER

    1,000,000

     

     

    7.

     

    SOLE DISPOSITIVE POWER

    0

     

     

    8.

     

     

    SHARED DISPOSITIVE POWER

    1,000,000

     

     

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,000,000

     

     

    10.

     

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    (SEE INSTRUCTIONS)

    o

     

     

    11.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    3.8% (See Note 1)

     

     

    12.

     

     

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

    PN

     

           

    (1)Based on 26,536,071 outstanding shares of Common Stock (as defined in Item 2(d) below) as of October 27, 2023 represented in the Issuer's 10-Q filed with the Securities and Exchange Commission ("SEC") on November 1, 2023.

     

     

    CUSIP No. 98888T10713G/APage 2 of 9 Pages

     

     

     

    1.

     

    NAME OF REPORTING PERSONS

    Kent Lake Capital LLC

     

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (see instructions)

    (a)     o

    (b)     o

     

     

    3.

     

    SEC USE ONLY

     

     

    4.

     

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH

     

    5.

     

    SOLE VOTING POWER

    0

     

     

    6.

     

    SHARED VOTING POWER

    1,000,000 (See Note 3)

     

     

    7.

     

    SOLE DISPOSITIVE POWER

    0

     

     

    8.

     

     

    SHARED DISPOSITIVE POWER

    1,000,000 (See Note 3)

     

     

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,000,000 (See Note 3)

     

     

    10.

     

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    (SEE INSTRUCTIONS)

    o

     

     

    11.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    3.8% (See Note 2)

     

     

    12.

     

     

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

    IA, HC

     

           

    (2)See Note (1) Above.

     

    (3)Pursuant to Rule 13d-4 under the Securities Exchange Act of 1934, as amended, Kent Lake Capital LLC expressly disclaims beneficial ownership over any of the securities reported in this statement, and the filing of this statement shall not be construed as an admission that Kent Lake Capital LLC is the beneficial owner of any of the securities reported herein.

    CUSIP No. 98888T10713G/APage 3 of 9 Pages

     

     

     

    1.

     

    NAME OF REPORTING PERSONS

    Benjamin Natter

     

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (see instructions)

    (a)     o

    (b)     o

     

     

    3.

     

    SEC USE ONLY

     

     

    4.

     

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH

     

    5.

     

    SOLE VOTING POWER

    0

     

     

    6.

     

    SHARED VOTING POWER

    1,000,000

     

     

    7.

     

    SOLE DISPOSITIVE POWER

    0

     

     

    8.

     

     

    SHARED DISPOSITIVE POWER

    1,000,000

     

     

     

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,000,000

     

     

    10.

     

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    (SEE INSTRUCTIONS)

    o

     

     

    11.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    3.8% (See Note 4)

     

     

    12.

     

     

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

    IN, HC

     

           

    (4) See Note (1) Above.

     

    CUSIP No. 98888T10713G/APage 4 of 9 Pages

     

    Item 1(a).Name of Issuer:

     

    ZimVie, Inc. (the “Issuer”)

     

    Item 1(b).Address of Issuer’s Principal Executive Offices:

     

    10225 Westmoor Drive

    Westminster, CO 80021

     

    Item 2(a).Name of Persons Filing:

     

    This statement is filed by the entities and persons listed below, who are collectively referred to herein as "Reporting Persons", with respect to the shares of Common Stock (as defined in Item 2(d) below) of the Company:

     

    (i)Kent Lake Partners LP

     

    (ii)Kent Lake Capital LLC

     

    (iii)Benjamin Natter

     

    Item 2(b).Address of Principal Business Office or, if none, Residence:

     

    (i)Kent Lake Partners LP

    c/o Kent Lake Capital LLC

    300 East 2nd Street, Suite 1510, #1033

    Reno, NV 89501

     

    (ii)Kent Lake Capital LLC

    300 East 2nd Street, Suite 1510, #1033

    Reno, NV 89501

     

    (iii)Benjamin Natter

    c/o Kent Lake Capital LLC

    300 East 2nd Street, Suite 1510, #1033

    Reno, NV 89501

     

    Item 2(c).Citizenship:

     

    (i)Kent Lake Partners LP – DE

     

    (ii)Kent Lake Capital LLC – DE

     

    (iii)Benjamin Natter – USA

     

    Item 2(d).Title of Class of Securities:

     

    Common Stock, $0.01 par value per share (“Common Stock”)

     

    Item 2(e).CUSIP Number:

     

    98888T107

     

    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

     

    Not Applicable.

     

    CUSIP No. 98888T107 13G/A Page 5 of 9 Pages

     

     

     

    Item 4.Ownership

     

    (i)Kent Lake Partners LP

     

    (a)Amount beneficially owned: 1,000,000 (See Note 5)

     

    (b)Percent of class: 3.8% (See Note 6)

     

    (c)Number of shares as to which the person has:

     

    (i)Sole power to vote or to direct the vote: 0

     

    (ii)Shared power to vote or to direct the vote: 1,000,000 (see Note 5)

     

    (iii)Sole power to dispose or to direct the disposition of: 0

     

    (iv)Shared power to dispose or to direct the disposition of: 1,000,000 (See Note 5)

     

    (ii)Kent Lake Capital LLC

     

    (a)Amount beneficially owned: 1,000,000 (See Note 5)

     

    (b)Percent of class: 3.8% (See Note 6)

     

    (c)Number of shares as to which the person has:

     

    (i)Sole power to vote or to direct the vote: 0

     

    (ii)Shared power to vote or to direct the vote: 1,000,000 (see Note 5)

     

    (iii)Sole power to dispose or to direct the disposition of: 0

     

    (iv)Shared power to dispose or to direct the disposition of: 1,000,000 (See Note 5)

     

    (iii)Benjamin Natter

     

    (a)Amount beneficially owned: 1,000,000 (See Note 5)

     

    (b)Percent of class: 3.8% (See Note 6)

     

    (c)Number of shares as to which the person has:

     

    (i)Sole power to vote or to direct the vote: 0

     

    (ii)Shared power to vote or to direct the vote: 1,000,000 (See Note 5)

     

    (iii)Sole power to dispose or to direct the disposition of: 0

     

    (iv)Shared power to dispose or to direct the disposition of: 1,000,000 (See Note 5)

     

    CUSIP No. 98888T107 13G/A Page 6 of 9 Pages

     

     

    Note 5:

     

    Kent Lake Capital LLC is an investment advisor that is registered under the Investment Advisors Act of 1940. Kent Lake Capital LLC may be deemed to be the beneficial owner of all shares of Common Stock held by Kent Lake Partners LP ("the Fund"). Mr. Benjamin Natter, as Managing Member of Kent Lake Capital LLC, with the power to exercise investment and voting discretion, may be deemed to be the beneficial owner of all shares of Common Stock held by the Fund. Pursuant to Rule 13d-4 under the Securities Exchange Act of 1934, as amended, Kent Lake Capital LLC and Mr. Natter expressly disclaim beneficial ownership over any of the securities reported in this statement, and the filing of this statement shall not be construed as an admission that Kent Lake Capital LLC or Mr. Natter are the beneficial owner of any of the securities reported herein.

     

    Note 6:

     

    Based on 26,536,071 outstanding shares of Common Stock as of October 27, 2023 represented in the Issuer's 10-Q filed with the SEC on November 1, 2023.

     

    Item 5.Ownership of Five Percent or Less of a Class:

     

    If this statetement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following [X].

      

    Item 6.Ownership of More Than Five Percent on Behalf of Another Person:

     

    Not Applicable.

      

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company:

     

    See Note 5 above.

     

    Item 8.Identification and Classification of Members of the Group:

     

    Not Applicable.

      

    Item 9.Notice of Dissolution of Group:

     

    Not Applicable.

      

    CUSIP No. 98888T107 13G/A Page 7 of 9 Pages

     

     

    Item 10.Certifications:

     

    Each of the Reporting Persons makes the following certification:

     

    By signing below each Reporting Person certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. After reasonable inquiry and to the best of my knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

     

     

    Date: February 14, 2024

     

     

     

    KENT LAKE PARTNERS LP

    By: Kent Lake GP LLC, its General Partner

    By: /s/ Benjamin Natter

    Name: Benjamin Natter

    Title: Managing Member

     

     

    KENT LAKE CAPITAL LLC

    By: /s/ Benjamin Natter

    Name: Benjamin Natter

    Title: Managing Member

     

     

    BENJAMIN NATTER

    By: /s/ Benjamin Natter

     

     

    CUSIP No. 98888T107 13G/A Page 8 of 9 Pages

     

     

    EXHIBIT A

     

    Joint Filing Agreement Pursuant to Rule 13d-1

     

    This agreement is made pursuant to Rule 13d-l(k)(1) under the Securities Exchange Act of 1934, as amended (the "Act") by and among the parties listed below, each referenced to herein as a "Joint Filer". The Joint Filers agree that a statement of beneficial ownership as required by Sections 13(g) or 13(d) of the Act and the rules thereunder may be filed on each of his, her or its behalf on Schedule 13G or Schedule 13D, as appropriate, and that said joint filing may thereafter be amended by further joint filings. The Joint Filers state that they each satisfy the requirements for making a joint filing under Rule 13d-1(k).

     

     

    Dated:  February 14, 2024
         

    KENT LAKE PARTNERS LP

    By: Kent Lake GP LLC, its General Partner

    By: /s/ Benjamin Natter

    Name: Benjamin Natter

    Title: Managing Member

     

     

    KENT LAKE CAPITAL LLC

    By: /s/ Benjamin Natter

    Name: Benjamin Natter

    Title: Managing Member

     

     

    BENJAMIN NATTER

    By: /s/ Benjamin Natter

     

     

     

     

    CUSIP No. 98888T107 13G/A Page 9 of 9 Pages

    Get the next $ZIMV alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ZIMV

    DatePrice TargetRatingAnalyst
    7/31/2025$19.00Buy → Neutral
    B. Riley Securities
    7/22/2025$19.00Underweight → Equal Weight
    Barclays
    4/10/2025$16.00Buy
    B. Riley Securities
    3/13/2025Buy → Hold
    Needham
    5/16/2024$20.00Hold → Buy
    Needham
    11/16/2023Hold
    Needham
    12/21/2022$9.00Underweight
    Barclays
    6/17/2022$20.00Neutral
    JP Morgan
    More analyst ratings

    $ZIMV
    SEC Filings

    View All

    SEC Form PREM14A filed by ZimVie Inc.

    PREM14A - ZimVie Inc. (0001876588) (Filer)

    8/15/25 5:02:32 PM ET
    $ZIMV
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by ZimVie Inc.

    SCHEDULE 13G/A - ZimVie Inc. (0001876588) (Subject)

    8/14/25 9:11:30 PM ET
    $ZIMV
    Medical/Dental Instruments
    Health Care

    SEC Form DEFA14A filed by ZimVie Inc.

    DEFA14A - ZimVie Inc. (0001876588) (Filer)

    7/30/25 4:15:04 PM ET
    $ZIMV
    Medical/Dental Instruments
    Health Care

    $ZIMV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ZimVie Reports Second Quarter 2025 Financial Results

    Recently entered into definitive agreement to be acquired by ARCHIMED for $19.00 in cash per shareNet Sales from Continuing Operations of $116.7 millionNet Loss from Continuing Operations of $(3.8) million; Net Loss margin of (3.3)% Adjusted EBITDA[1] from Continuing Operations of $17.5 million; Adjusted EBITDA[1] margin of 15.0%GAAP diluted EPS from Continuing Operations of $(0.14) and adjusted diluted EPS[1] from Continuing Operations of $0.26 PALM BEACH GARDENS, Fla., July 30, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental implant market, today reported financial results for the quarter ended June 30, 2025. "Our results this quarter ref

    7/30/25 4:05:00 PM ET
    $ZIMV
    Medical/Dental Instruments
    Health Care

    ZimVie to Report Second Quarter 2025 Financial Results on July 30, 2025

    PALM BEACH GARDENS, Fla., July 25, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental implant market, today announced it will report financial results for the second quarter 2025 and file its Quarterly Report on Form 10-Q after market close on Wednesday, July 30, 2025. On July 21, 2025, ZimVie issued a press release announcing ZimVie's entry into a definitive agreement pursuant to which ZimVie will be acquired by an affiliate of ARCHIMED ("ARCHIMED") for $19.00 in cash per share. A copy of that press release is accessible by visiting the "Investor Relations" section of ZimVie's website. The transaction is expected to close by year-end 2025, su

    7/25/25 8:00:00 AM ET
    $ZIMV
    Medical/Dental Instruments
    Health Care

    ZimVie Announces Exclusive Distribution Agreement with Osstem Implant to Expand Premium Dental Implant Offering in China

    PALM BEACH GARDENS, Fla., July 23, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental implant market, today announced a strategic distribution agreement with Osstem Implant Co., Ltd. ("Osstem Implant"), a leading dental solutions provider specializing in high-quality implants and integrated dental technologies globally. The agreement expands ZimVie's global presence to further penetrate the large, growing Chinese implant market—estimated at greater than 10 million units annually1—and enhance customer access to its innovative implant portfolio. Osstem Implant is the market-leading provider of dental implants in China, with broad, established dis

    7/23/25 4:05:00 PM ET
    $ZIMV
    Medical/Dental Instruments
    Health Care

    $ZIMV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Kanaglekar Indraneel covered exercise/tax liability with 145 shares, decreasing direct ownership by 0.23% to 62,851 units (SEC Form 4)

    4 - ZimVie Inc. (0001876588) (Issuer)

    7/3/25 4:17:15 PM ET
    $ZIMV
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Director Kuntz Richard

    4 - ZimVie Inc. (0001876588) (Issuer)

    7/2/25 4:36:01 PM ET
    $ZIMV
    Medical/Dental Instruments
    Health Care

    Chief Accounting Officer Schneider Sandra converted options into 11,127 shares and covered exercise/tax liability with 2,710 shares, increasing direct ownership by 26% to 40,794 units (SEC Form 4)

    4 - ZimVie Inc. (0001876588) (Issuer)

    5/19/25 4:18:13 PM ET
    $ZIMV
    Medical/Dental Instruments
    Health Care

    $ZIMV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    ZimVie downgraded by B. Riley Securities with a new price target

    B. Riley Securities downgraded ZimVie from Buy to Neutral and set a new price target of $19.00

    7/31/25 7:17:57 AM ET
    $ZIMV
    Medical/Dental Instruments
    Health Care

    ZimVie upgraded by Barclays with a new price target

    Barclays upgraded ZimVie from Underweight to Equal Weight and set a new price target of $19.00

    7/22/25 10:21:16 AM ET
    $ZIMV
    Medical/Dental Instruments
    Health Care

    B. Riley Securities initiated coverage on ZimVie with a new price target

    B. Riley Securities initiated coverage of ZimVie with a rating of Buy and set a new price target of $16.00

    4/10/25 12:44:28 PM ET
    $ZIMV
    Medical/Dental Instruments
    Health Care

    $ZIMV
    Leadership Updates

    Live Leadership Updates

    View All

    ZimVie Announces Upcoming Changes to Company's Board of Directors

    PALM BEACH GARDENS, Fla., March 13, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental implant market, today announced upcoming changes to the Company's Board of Directors, including:  Non-Executive Chair David King will not stand for reelection as a director upon the expiration of his current term at the Company's annual meeting of shareholders on May 7, 2025.President and CEO Vafa Jamali will be appointed Chairman of the Board effective as of May 7, 2025.Director Vinit Asar will be appointed Lead Independent Director effective upon the commencement of Mr. Jamali's service as Chairman. Retirement of Mr. King "On behalf of ZimVie and our Boar

    3/13/25 4:15:00 PM ET
    $ZIMV
    Medical/Dental Instruments
    Health Care

    Veradigm Announces Board Expansion and Changes

    Appoints Vinit Asar and Louis Silverman to its Board of Directors Agrees to Add Two Additional Directors Veradigm® (OTC:MDRX) ("Veradigm" or the "Company"), a leading provider of healthcare data and technology solutions, announced today it has entered into a Cooperation Agreement (the "Agreement") with Kent Lake PR LLC ("Kent Lake"). The Agreement aligns with the Board's request for input from shareholders regarding board composition on January 30, 2025, and a desire to conduct an orderly refreshment of the Board following the conclusion of the exploration of strategic alternatives. As part of the Agreement, the Board has appointed two new independent directors, Vinit Asar and Louis Silve

    2/20/25 4:02:00 PM ET
    $MDRX
    $OCX
    $ZIMV
    EDP Services
    Technology
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ZIMV
    Financials

    Live finance-specific insights

    View All

    ZimVie Reports Second Quarter 2025 Financial Results

    Recently entered into definitive agreement to be acquired by ARCHIMED for $19.00 in cash per shareNet Sales from Continuing Operations of $116.7 millionNet Loss from Continuing Operations of $(3.8) million; Net Loss margin of (3.3)% Adjusted EBITDA[1] from Continuing Operations of $17.5 million; Adjusted EBITDA[1] margin of 15.0%GAAP diluted EPS from Continuing Operations of $(0.14) and adjusted diluted EPS[1] from Continuing Operations of $0.26 PALM BEACH GARDENS, Fla., July 30, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental implant market, today reported financial results for the quarter ended June 30, 2025. "Our results this quarter ref

    7/30/25 4:05:00 PM ET
    $ZIMV
    Medical/Dental Instruments
    Health Care

    ZimVie to Report Second Quarter 2025 Financial Results on July 30, 2025

    PALM BEACH GARDENS, Fla., July 25, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental implant market, today announced it will report financial results for the second quarter 2025 and file its Quarterly Report on Form 10-Q after market close on Wednesday, July 30, 2025. On July 21, 2025, ZimVie issued a press release announcing ZimVie's entry into a definitive agreement pursuant to which ZimVie will be acquired by an affiliate of ARCHIMED ("ARCHIMED") for $19.00 in cash per share. A copy of that press release is accessible by visiting the "Investor Relations" section of ZimVie's website. The transaction is expected to close by year-end 2025, su

    7/25/25 8:00:00 AM ET
    $ZIMV
    Medical/Dental Instruments
    Health Care

    ZimVie Reports First Quarter 2025 Financial Results

    Net Sales from Continuing Operations of $112.0 millionNet Loss from Continuing Operations of $(2.6) million; Net Loss margin of (2.3)% Adjusted EBITDA[1] from Continuing Operations of $17.6 million; Adjusted EBITDA[1] margin of 15.7%GAAP diluted EPS from Continuing Operations of $(0.09) and adjusted diluted EPS[1] from Continuing Operations of $0.27 PALM BEACH GARDENS, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (NASDAQ:ZIMV), a global life sciences leader in the dental market, today reported financial results for the quarter ended March 31, 2025. Management will host a corresponding conference call today, May 8, 2025, at 4:30 p.m. Eastern Time. "We are proud to have entered 2025

    5/8/25 4:05:00 PM ET
    $ZIMV
    Medical/Dental Instruments
    Health Care

    $ZIMV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by ZimVie Inc.

    SC 13G - ZimVie Inc. (0001876588) (Subject)

    11/14/24 4:11:11 PM ET
    $ZIMV
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by ZimVie Inc.

    SC 13G/A - ZimVie Inc. (0001876588) (Subject)

    11/14/24 10:58:06 AM ET
    $ZIMV
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by ZimVie Inc.

    SC 13G/A - ZimVie Inc. (0001876588) (Subject)

    10/4/24 1:02:25 PM ET
    $ZIMV
    Medical/Dental Instruments
    Health Care